Companion Diagnostics Markets: The Future of Diagnostics by Application, Technology and Funding with Executive and Consultant Guides 2024 to 2028
“Companion Diagnostics (CDx) are changing cancer management and poised to move into new therapeutic areas. Dawn of a new age in medical treatment….”
Page count: 546
Publication date: September 2023
Companion Diagnostics (CDx) are poised to revolutionize the diagnostics industry. The market is moving out of the lab and into the clinic. Oncology, particularly immuno-oncology is leading the way and the FDA is holding the door open for this diagnostic technology of the future. Understand the latest outlook for this highly important market.
Will Personalized Companion Diagnostics become the norm?
Learn how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new significant business opportunities, with some players already taking the lead. A dynamic market situation with enormous opportunity, diagnostic companies are trying to back the right horse. The science is racing forward and the cost of molecular diagnostics continues to fall.
Use this new report to forecast demand for new testing regimes and/or technologies and make confident research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Hundreds of pages of information including a complete list of current United States Medicare Fee Payment Schedules to help understand the new Nucleic Acid Test (NAT) pricing in detail. Forecast demand for new testing regimes or technologies.
The report includes detailed breakouts for 18 countries and 4 regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options, however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
All report data is available in Excel format on request with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School